Influence of valsartan combined carvedilol on heart function and myocardial remodeling in patients with heart failure with preserved ejection fraction / 心血管康复医学杂志

ABSTRACT

Objective: To study therapeutic effect of valsartan combined carvedilol on patients with heart failure with preserved ejection fraction (HFPEF) and its influence on heart function and myocardial remodeling. Methods: A total of 92 aged HFPEF patients treated in our hospital were selected. They were randomly and equally divided into routine treatment group and combined treatment group (received valsartan combined carvedilol based on routine treatment), and both groups were treated for six months. Therapeutic effect, heart function, myocardial remodeling indexes and adverse reactions were compared between two groups after six months. Results: Total effective rate of combined treatment group was significantly higher than that of routine treatment group (93. 48％ vs. 78. 26％, P=0. 036). Compared with routine treatment group after treatment, there were significant reductions in blood pressure [(120. 26±9. 17) / (73. 56±5. 86) mmHg vs. (115. 68±10. 31) / (67. 24±4. 92) mmHg], heart rate [(74. 35±8. 53) beats/min vs. (68. 48±7. 17) beats/min]and BNP level [(299. 86±19. 43) pg/ml vs. (231. 71± 20. 15) pg/ml], significant rise in E/A [(1. 02±0. 09) vs. (1. 26±0. 07)] and LVEF [(53. 14±1. 60) ％ vs. (57. 02±1. 51) ％]; and significant reductions in IVRT [(119. 45±14. 23) ms vs. (102. 17±11. 53) ms], LAVI [(35. 82±7. 15) ml/m2 vs. (30. 17±6. 48) ml/m2], LVEDd [(57. 22±7. 24) mm vs. (50. 61±6. 35) mm]and LVESd [(50. 14±5. 06) mm vs. (44. 93±5. 82) mm]in combined treatment group, P＜0. 05 or＜0. 01. During treatment, no obvious adverse reactions occurred in two groups. Conclusion: Valsartan combined carvedilol can significantly increase effective rate, improve heart function and myocardial construction in HFPEF patients. Which is worth extending.